Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 57.00p 56.75p 58.00p 61.00p 57.00p 58.00p 272,104 16:11:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -6.3 -4.5 - 75.54

Immupharma Share Discussion Threads

Showing 8276 to 8300 of 8300 messages
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
DateSubjectAuthorDiscuss
23/7/2017
19:34
Yes Glen. Furthermore the continued good safety profile bodes well for Lupuzor meeting any Phase III secondary endpoint test on suicidality.
top tips
23/7/2017
19:32
Update on Pivotal Phase III Lupuzor Study, 30/6/2017 http://uk.advfn.com/stock-market/london/immupharma-IMM/share-news/Immupharma-PLC-Update-on-LupuzorT-Pivotal-Phase-II/75145114 "Continued robust safety record which remains consistent with Lupuzor™’s product profile as shown in its previous Phase IIb study..." "...As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor™ is being administered to greater numbers of patients over a longer period of time." --------------------------------- Presentation, 30/6/2017 hTTp://www.immupharma.org/sites/default/modules/immu/downloads/IMM-presentation-june-2017.pdf Slide 25 Lupuzor™ phase III trial - study highlights "Continued robust safety record which remains consistent with Lupuzor™’s product profile as shown in its previous Phase IIb study" --------------------------------- Interview, with Tim Mc Carthy, 17/5/2017 Lupuzor safety profile 'holding up' - ImmuPharma's Tim McCarthy updates on Phase III study 2 min 15 sec. onwards: hTTps://www.youtube.com/watch?v=kE2AZM2qPUk "To date in all our studies we have shown a very very good profile...what we can monitor as we go through the (Phase III) study is that if there are any obvious safety issues or side effects then we would know about it and certainly if they were serious we would have to announce that, we are not seeing any of that at the moment. The product profile is holding up, the passage of time is important...the fact we now have all 200 patients in the study...over 80% of patients have gone through 6 months and a number have completed the whole 12 months study...and the product profile in terms of the safety is still holding up, that is a really good signal - a really good signal, because it means the drug is being well tolerated..." --------------------------------
top tips
23/7/2017
19:31
Yes I can see that after 6 months on a drug trial and if there were no signs at all of improvement one might well be tempted to drop out. So from that point of view we could infer positive outcome perhaps.
glennrcharles
23/7/2017
18:52
Update on Pivotal Phase III Lupuzor Study, 30/6/2017 http://uk.advfn.com/stock-market/london/immupharma-IMM/share-news/Immupharma-PLC-Update-on-LupuzorT-Pivotal-Phase-II/75145114 "Continued robust safety record which remains consistent with Lupuzor™’s product profile as shown in its previous Phase IIb study..." "...As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor™ is being administered to greater numbers of patients over a longer period of time." --------------------------------- Presentation, 30/6/2017 hTTp://www.immupharma.org/sites/default/modules/immu/downloads/IMM-presentation-june-2017.pdf Slide 25 Lupuzor™ phase III trial - study highlights "Continued robust safety record which remains consistent with Lupuzor™’s product profile as shown in its previous Phase IIb study" --------------------------------- Interview, with Tim Mc Carthy, 17/5/2017 Lupuzor safety profile 'holding up' - ImmuPharma's Tim McCarthy updates on Phase III study 2 min 15 sec. onwards: hTTps://www.youtube.com/watch?v=kE2AZM2qPUk "...To date in all our studies we have shown a very very good profile...what we can monitor as we go through the (Phase III) study is that if there are any obvious safety issues or side effects then we would know about it and certainly if they were serious we would have to announce that, we are not seeing any of that at the moment. The product profile is holding up, the passage of time is important...the fact we now have all 200 patients in the study...over 80% of patients have gone through 6 months and a number have completed the whole 12 months study...and the product profile in terms of the safety is still holding up, that is a really good signal - a really good signal, because it means the drug is being well tolerated..." --------------------------------
top tips
23/7/2017
18:47
There are excellent discussions on this board, not every one shares the same opinion and we do get trolls bashing the share and others trying to ramp the share. The people who have been here for several years know the potential and just sit and wait, but perhaps even the rampers can bring new short and long time investors to look at this share, and help push the share price to a more realistic level. It can be frustrating that the price doesnt reflect the true potential of p140 and nucant, urelix,
barriew
23/7/2017
18:16
I'm just quoting what is in their press releases and what they have said at presentations and interviews.
top tips
23/7/2017
12:21
You give a monkey a share portfolio and a bulletin board profile and they immediately think they are king of the corporate jungle.Top Tips, you seem to be trying hard to stoke up a rumour mill to generate a short term speculative bubble from which to profit. I don't mind, but please lay off trying to sound like you know what you are talking about. You clearly know very little about this company, Lupuzor or the mechanics of a phase 3 drug trial.
longshanks
21/7/2017
19:42
A positive review by the DSMB with a decision to allow the trial to continue is one thing, suggesting that the BOD have been tipped off re. success of the trial, efficacy or even safety versus placebo is quite another.
bermudashorts
21/7/2017
19:34
bermudashorts, the Phase III Lupuzor trial is double blinded so obviously IMM do not have efficacy readout until it is complete. However in their updates, including on 30/6/2017, they mentioned: http://uk.advfn.com/stock-market/london/immupharma-IMM/share-news/Immupharma-PLC-Update-on-LupuzorT-Pivotal-Phase-II/75145114 "Continued robust safety record which remains consistent with Lupuzor(TM)'s product profile as shown in its previous Phase IIb study" "As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor(TM) is being administered to greater numbers of patients over a longer period of time." Robert Zimmer also recently mentioned a low patient drop out rate for the Lupuzor trial in comparison to Benlysta trials. The inference is you drop out early if the drug being taken is not working for you or produces adverse side effects (Benlysta), and conversley stay in if it is working or does not have adverse side effects (Lupuzor). So it seems they do at least get or can infer some informaton about Lupuzor's ongoing safety profile (and/or efficacy) arising from the Phase III trial as it progresses, and this feedback seems to be excellent. This is particularly important as already marketed drug Benlysta apparently produces unpleasent side effects, implying on this parameter at least Lupuzor appears to have a clear advantage over Benlysta, which for me helps to derisk Lupuzor. Tim McC has mentioned this in all his recent presentations so it is obviously important. I will be accumulating and holding for the Phase III results. Like Tim McC said, he has been in the business for 30 years and has never been so excited as much as he is about Lupuzor. Apparently they have found the exact peptide needed according to a video presentation.
top tips
21/7/2017
19:24
hottingup 21 Jul '17 - 17:51 - 2901 of 2903    2   0 Don't analyse things too closely. The second sentence of top tip's last post hit the mark. Just give it time. ================================================================================= Which was ''Demand for the stock should increase even more as the Phase 3 results get nearer.'' I agree it should, but who knows if the II's start de-risking before then? What I do know is that you and top tips will be long gone before Q1 2018, probably in a few weeks.
pj 1
21/7/2017
19:11
ctrlseng - that is simply untrue. 1) Usually, the different arms of the trial are simply marked X and Y, so members of the DSMB won't know if they're looking at data from the treatment arm or control arm. 2) The DSMB will be dealing with the CRO and don't have a hot line to the BOD 3) Any suspicion whatsoever of information coming from the DSMB to anybody, let alone the trial sponsor would compromise the trial and could well invalidate the results. 4) There is no doubt that Sylviane Muller and Robert Zimmer truly believe in the efficacy of Lupuzor. The BOD's confidence in the trial results is simply a reflection of that and anyone who suggests that it's based on anything else is either kidding themselves or trying to kid others.
bermudashorts
21/7/2017
18:09
GlennRCharles, Bermudashorts: Data Monitoring Committee maight be independent experts but reality is that they know the difference between control groups and BOD may have an unofficial access to the research. McCarthy said: "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This (Lupuzor) is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug." No one with common sense says things like that without being sure what he is saying.
ctrlseng
21/7/2017
17:51
Don't analyse things too closely. The second sentence of top tip's last post hit the mark. Just give it time.
hottingup
21/7/2017
17:31
Someone is selling into strength (edit de-risking?), todays price action was almost bizarre. Aviva?
pj 1
21/7/2017
17:11
Good to see IMM briefly trading over 60p today and mainly buys. Demand for the stock should increase even more as the Phase 3 results get nearer. A little over 100 trading days until the end of December. Not long to wait now.
top tips
21/7/2017
14:28
Lupuzor has $2-3 Billion Market Potential / Market Cap laughable £79 Million / Upfront payment from potential partnership for US rights alone could bring more than the £79 Million = Immupharma should be over £300 right now and a Billion Dollar Company after positive phase 3 results = STRONG BUY
ih_116147
21/7/2017
14:27
I sold my UKOG at a nice profit and am happy to invest here which i see 100x the current price within eight months if all goes well and bearing in mind Lupuzor could treat other blockbuster health problems. Gut feeling that Mauritius will approve Lupuzor really quickly as they have their own regulatory system and asked to be included in the PIII trial so will have a large sub set of data. £20 easy before Phase III results in Feb '18, then £50+ after the results.
money maker1
21/7/2017
14:27
I sold my UKOG at a nice profit and am happy to invest here which i see 100x the current price within eight months if all goes well and bearing in mind Lupuzor could treat other blockbuster health problems. Gut feeling that Mauritius will approve Lupuzor really quickly as they have their own regulatory system and asked to be included in the PIII trial so will have a large sub set of data. £20 easy before Phase III results in Feb '18, then £50+ after the results.
money maker1
21/7/2017
14:06
Some action since I last looked in. I've increased my holding this morning at 59p and won't be buying any more! As I understand it,the window is now less than six months to the stage 3 read out, so I'm expecting £1 before that time, and certainly, 70p in short order, once the 60 resistance is broken.
brucie5
21/7/2017
12:15
Hi Bermudashorts, sorry I missed your reply somehow. Thanks for that clarification. Much appreciated.
luminoso
21/7/2017
12:03
Can't get a buy quote for just £1k.
someuwin
21/7/2017
12:00
Spread is now 0.8%, (the lowest I've seen for some time)
pj 1
21/7/2017
11:53
Thanks. Pity..lol
glennrcharles
21/7/2017
11:49
lol - the Data Monitoring Committee is a panel made up of completely independent experts. Their job is to review unblinded data during the trial at pre-agreed intervals eg. after a set no. of patients have been dosed or after a certain no. of adverse events. Their job is to monitor safety and efficacy and if they're happy they'll allow the trial to continue but if they have concerns they can halt the trial. One thing I'm sure about though is that there is zero chance of the DMC giving the BOD the nod as it were.
bermudashorts
21/7/2017
11:43
I think you may see one.. once we're past 60p.
brucie5
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170724 00:57:19